Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

GT Healthcare Capital Partners

Investor type Venture Capital
Founders Alan Au


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
The average size of a deal this fund participated in
Portfolio companies 12
Rounds per year 2.86
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Key employees 4
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Artificial Intelligence
  • Medical Device
  • Pharmaceutical

In 2015 was created GT Healthcare Capital Partners, which is appeared as VC. The main department of described VC is located in the Hong Kong. The fund was located in Asia if to be more exact in Hong Kong.

The fund was created by Alan Au. Besides them, we counted 4 critical employees of this fund in our database.

The important activity for fund was in 2019. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. The typical startup value when the investment from GT Healthcare Capital Partners is more than 1 billion dollars.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Medical Device. Among the most popular portfolio startups of the fund, we may highlight Oxford Nanopore Technologies, Oxford VR, Ultromics. The fund has specific favorite in a number of founders of portfolio startups.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the GT Healthcare Capital Partners, startups are often financed by Venrock, Sofinnova Partners, Pfizer Venture Investments. The meaningful sponsors for the fund in investment in the same round are Sonder Capital, Oxford Sciences Innovation, Vertex Ventures. In the next rounds fund is usually obtained by Oxford Finance LLC, Hostplus, GIC.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of GT Healthcare Capital Partners:
Typical Co-investors
GT Healthcare Capital Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after GT Healthcare Capital Partners:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Anhui Kexun Venture Capital -
Arris Group Georgia, Suwanee, United States
B37 Ventures California, San Francisco, United States
BizTEC Hefa, Hefa, Israel
Blackbelt Properties -
Capitech China, Shaanxi, Xian Shi
Cirrus Logic Austin, Texas, United States
Diversified Systems Kenilworth, New Jersey, United States
GWN Ltd -
HSBC Securities New York, New York, United States
Invaluable Allston, Massachusetts, United States
Lanying Materials Trade China, Jiangsu, Suzhou
Lichtsteiner Foundation Bern, Berne, Switzerland
Monachil Capital Partners LP Connecticut, Greenwich, United States
Mosaix Ventures Chicago, Illinois, United States
Rally Capital -
RedMetal Massachusetts, United States, Watertown
Shenzhen Renyuan Guoying Touzi Guanli Qiye (Youxian Hehuo) China, Guangdong, Shenzhen
St George Bank Australia, New South Wales, Sydney
Zhonglian Investment Holdings China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Moon Surgical

Health Care
Medical Device
$31M07 Jun 2022 Paris, Ile-de-France, France

Health Care
Life Science
$105M28 Apr 2021 San Diego, California, United States


Artificial Intelligence
Health Care
$225M27 Apr 2021 Oxford, England, United Kingdom


Artificial Intelligence
Health Care
$225M20 Apr 2021 Oxford, England, United Kingdom


Artificial Intelligence
Health Care
$40M04 Mar 2021 Oxford, England, United Kingdom

G.I. Windows

Health Care
Medical Device
$16M19 Aug 2020 Massachusetts, United States


Artificial Intelligence
Health Care
$60M26 May 2020 Oxford, England, United Kingdom

Oxford VR

Health Care
Virtual Reality
$13M12 Feb 2020 United Kingdom, England

Zap Surgical Systems

Medical Device
$81M08 Jan 2020 California, United States
Exscientia Raises Up To $525M in Funding

– Exscientia is an Oxford, England, UK-based clinical stage pharmatech company using AI to design patient-based drugs.
SoftBank Vision Fund 2 led the Series D funding round and was joined by previous round lead investors – Novo Holdings and funds managed by Blackrock.
– Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb.
– In addition to the Series D funding round, SoftBank is providing an additional $300m equity commitment that can be drawn at the company’s discretion.

Exscientia Closes $100M in Series C Financing

– Exscientia is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs.
– Company raised 100m in Series C funding.
– The round was led by BlackRock with participation from Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.
– The company intends to use the funds for platform development towards autonomous drug design, extension of its proprietary pipeline into clinical trials and expansion of existing capabilities in biological analytics that support target selection and portfolio development.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent GT Healthcare Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: